Study Evaluating Genotypes Using Lucentis

• Status: Terminated
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Treatment naive AMD patients;

• At least 50 years of age;

• Visual acuity between 20/40 and 20/320

Exclusion Criteria:

• Pregnancy;

• Prior enrollment in a ranibizumab clinical trial;

• Previous therapy in either eye for AMD;

• Concurrent eye disease that could compromise visual acuity